Targeting mTOR and prenylation by Farrugia, Mario et al.
  
 
 
The mTOR inhibitor, rapamycin, sensitises solid tumour cell 
lines to isoprenoid induced toxicity. 
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ABSTRACT 
 
Protein prenylation is a post-translational addition of a lipophilic farnesyl or geranylgeranyl moiety derived 
from the pyrophosphate substrates, intermediates of the mevalonate pathway.   Prenylation of Ras-related 
small GTP-binding proteins and heterotrimeric G proteins constitute protein activation events associated 
with cellular proliferation.  The monoterpenes limonene and perillyl alcohol inhibit protein isoprenylation 
resulting in cell cycle arrest and induction of apoptosis.  Clinical trials of d-limonene and perillyl alcohol 
resulted in dose limiting toxicity.  Reducing the dosage of isoprenoids, while maintaining the anti-
proliferative effect is a challenge.  Interestingly, the limiting factor of the mevalonate pathway, HMG CoA 
reductase, is controlled at translation level and hence sensitive to mTOR activity.  The purpose of this study 
was to investigate the dose response using a combinatory treatment of isoprenoids and rapamycin (mTOR 
inhibitor), on various solid tumour cell line models. 3 solid tumour cell lines, namely PC3 (prostate) C32 
(melanoma) and A549 (lung), were chosen on the basis of sensitivity to the mTOR inhibitor, rapamycin.  
Cytotoxicity assays using XTT were performed on the cell lines treated with Limonene, Perillyl alcohol and 
α-Pinene. In this study XTT assays were used to quantify viable cells after treatment with Isoprenoids and 
Rapamycin alone  or  in  combination. Dosages at IC50s were used to measure apoptosis by Annexin V 
staining and flow cytometry.  The  C32 and PC3 cell lines were sensitive to rapamycin  treatment, resulting 
in a decrease  in cell viability by more than 20%, but retaining  a  constant  growth  curve thereafter. A549 
was not sensitive to rapamycin at all concentrations tested. For all combinatory treatments, 50ng/ml 
rapamycin was selected.  The viability of PC3 and C32 cell lines decreased significantly by the combinatory 
effect of 50ng/ml rapamycin and isoprenoids.  Although cell death was enhanced after sensitisation with 
rapamycin, other mechanisms of loss of cellular viability, other than apoptosis, have a major role.   Our 
results show a statistically significant reduction in IC50 of various isoprenoids, following pre-sensitization 
with 50ng/ml of rapamycin in the prostate cell line (PC3) and the melanoma cell line (C32). Hence this 
novel combination of drugs targeting two mechanisms that converge on a common target, provide a higher 
efficacy compared to using either drug on its own.  This merits further investigation to characterise the 
mechanism/s of viability suppression in the solid tumour cellular models. 
 
 
 
 
 
INTRODUCTION 
 
Protein activation involves the post translational modifications, prenylation and phosphorylation.  
Protein prenylation is a post-translational addition of a lipophilic farnesyl or geranylgeranyl moiety 
at a Cys residue derived from the pyrophosphate substrates, intermediates of the mevalonate 
pathway [1]. Prenylation of Ras-related small GTP-binding proteins, heterotrimeric G proteins and 
nuclear lamins [2] constitute protein activation events associated with cellular proliferation.  The 
monoterpenes limonene and perillyl alcohol inhibit protein isoprenylation as a result of suppressed 
3-hydroxy-3-methylglutaryl (HMG) CoA reductase activity, supporting the role of monoterpenes as 
anti-proliferative agents [2, 3].   Inhibition of HMG CoA reductase, results in cell cycle arrest and 
induction of apoptosis [4, 5].  In addition, limonene and its derivative perillyl alcohol inhibit NF-kB 
signaling promoting apoptosis [6], resulting in suppressed proliferation and metastasis of gastric 
cancer [7], mammary and pancreatic tumors [8].  Another monoterpene, a-pinene is a potent 
inhibitor of NF-kB and exerts its function as an inhibitor of inflammatory responses [9].     
 
The anti-proliferative capacity of perillyl alcohol was investigated in several phase I trials in 
patients with high grade malignancies [10] and solid tumours [11] and Phase II trials in patients 
with metastatic prostate cancer [12], advanced ovarian cancer [13], and metastatic colorectal 
cancer [14].    Dose limiting toxicity of d-limonene and perillyl alcohol in clinical trials includes 
nausea, vomiting, hypokalemia, anorexia and eructation [11, 15].  Reducing the dosage of 
isoprenoids while maintaining the anti-proliferative effect, is a challenge.   
 
mTOR inhibition has been  combined  with  other agents to enhance  antitumour  effect of other  
therapies [16-18].   To support the proposed combination of inhibitors, previous studies show that  
simultaneous inhibition of the Ras/Raf/MEK/ERK (MAPK) and the PTEN/PI3K/AKT/mTOR 
pathways results in upregulation of pro-apoptotic molecules such as members of the BCL-2 family 
of pro-apoptotic proteins, like Bim and Bad [19].  In addition, co-targeting the ras/MEK  and the 
AKT/mTOR pathway in malignant melanoma provide a treatment option for acquired resistance 
during therapy [20].   
 
Of interest, the translation of the HMG CoA reductase transcript is sensitive to the availability of 
the eukaryotic Initiation Factor 4E (eIF4E) [21].  Hence the phosphorylation of the eIF4E binding 
protein, 4EBP1 ensures release of eIF4E for translation initiation of structured transcripts that are 
otherwise not translated [22].  4EBP1 is phosphorylated by the mammalian target of rapamycin, 
mTOR.  Inhibition of mTOR using rapamycin results in sequestration of eIF4E into a 4EBP1 
complex and a shift from cap-dependent to cap-independent translation initiation.  Studies using 
the in vitro cellular models for prostate and melanoma, characterized the deregulation of Akt and 
ras pathways as being central to the progression of the disease [23].  Growth and progression of 
these tumours is associated with constitutive activation of mTOR [24].    This supports the 
rationale to inhibit both the Akt/mTOR and ras pathways with potential synergistic effect to 
attenuate cell growth and proliferation.  In this study we investigated a panel of tumour cell lines 
for sensitivity to low dose rapamycin and selected 2 sensitive cell lines, namely the prostate 
cancer cell line, PC3 and melanoma cell line, C32 to study the synergistic effect of isoprenoids.  
The rapamycin resistant cell line A549 (basal epithelial cells) was included in the study. 
 
 
 
MATERIALS AND METHODS 
 
Cell lines, Media and Reagents:  3 solid tumour cell lines were chosen from a panel of cell lines. 
PC3 (ATCC CRL-1435; prostate) and C32 (ATCC CRL-1585; melanoma) cultured in DMEM + 
10% FBS. A549 (ATCC CCL-185; lung epithelial) cultured in RPMI + 10% FBS. All cell lines were 
incubated at 37°C in a 5% CO2/95% air atmosphere.  Pharmacological inhibitors used include 
rapamycin (Alexis  Biochemicals,  San  Diego,  CA), Limonene, Perillyl alcohol (Sigma-Aldrich 
Chemie GmbH, Germany), α-Pinene (Fluka, Sigma-Aldrich Chemie GmbH, Germany). 
 
Cytotoxicity assays using XTT were performed on all cell lines. The assay is based on the 
cleavage of the   yellow   tetrazolium   salt   XTT   to   form an   orange   formazan   dye  by  
mitochondrial dehydrogenases  in viable cells. Cells grown in 96 microtiter plates for 24, 48 and 
72hrs and were  incubated  with  XTT  solution  and  activator  solution  (Cell  Proliferation  Kit,  
Biological Industries, Beit Haemek, Israel) for 2-24hrs before reading on microplate reader.   In the 
study XTT assays were used to quantify viable cells after treatment with Isoprenoids and 
Rapamycin alone or in combination.  Rapamycin  stock  solution  (1mg/ml)  was  used  to  yield  7 
concentrations (25, 50, 75, 100, 150, 200, 300ng/ml), while a stock solution (400μg/ml) of each 
isoprenoid was used to prepare  a range of concentrations (0, 2, 10, 20, 40, 60, 80, 160 ppm). The 
combinatory experiment involved addition of 50ng/ml rapamycin to the range of each test 
isoprenoid. 
 
Annexin V/Propidium iodide apoptotic assay was used to measure the decline of viable cells and 
the appearance of early apoptotic and late apoptotic/necrotic cells in one assay. Cells were left in 
6-well plates in duplicates and incubated with test drugs. IC50s obtained from XTT results were 
used for treatment of each cell line. Every cell line encompassed (1) steady state (SS) cells and 
(2) 50ng/ml Rapamycin treatment, (3) each isoprenoid added alone and (4) in combination with 
50ng/ml rapamycin. 1 x 105–1 x 106 cells were harvested and centrifuged. 2mL suspension was  
centrifuged  and  the pellet  was  resuspended   in  500uL  1X  binding  buffer  (Annexin  V-FITC 
Apoptosis Kit Plus, Biovision, Mountain View, CA 94043 USA). 5μL of Annexin-V antibody and 
5μL Propidium iodide were added and cells were incubated for 5-15 minutes in the dark and read 
by flow cytometry (Bryte-HS, Bio-Rad Laboratories, Hercules, CA, USA). 
 
 
 
 
 
 
RESULTS AND DISCUSSION 
 
This study aims to establish a combinatory treatment of isoprenoids with rapamycin, to improve 
efficacy of isoprenoid chemotherapeutic effect at lower dosages.   The sensitivity to rapamycin 
was determined using XTT viability assays.  The cell lines PC3 and C32 show a marked reduction 
of cell proliferation following addition of 50ng/ml rapamycin.  This reduced proliferation was 
maintained at higher dosages, but rapamycin did not induce a cytotoxic effect, hence we score this 
as sensitization of the cell lines that retain cell cycle progression.  Of interest, the PC3 and C32 
cell lines have mutations in the phosphatase PTEN.  PTEN mutations increase activity of 
PI3K/Akt/mTOR pathway and this can explain the sensitivity to the mTOR inihibtor, rapamycin. In 
this study, rapamycin sensitive cell lines, resulted in a decrease in proliferation at a concentration 
of 50ng/ml and a decreased ED50 in combinatory treatment with all isoprenoids tested.  In 
contrast, cytotoxicity assays of A549  did  not  show sensitivity towards  rapamycin  alone,  and  
combination  of the  three isoprenoids with rapamycin did not decrease  ED50, possibly because 
the cell line is PTEN wild-type.   
 
 
 
PC3 and C32 are sensitive to low dose rapamycin 
 To assess the sensitivity of the cell lines to rapamycin, we exposed the cells to different 
doses of rapamycin and measured the loss of viability at 3 time points (24, 48 and 72 hours).  Of 
interest, in both PC3 and C32, a dose of 50ng/ml rapamycin resulted in a suppression of cell 
viability by more than 20% at 48hours and retained a constant viability at higher doses of the drug 
(Figure 1 A-B).  This sensitization of the cell lines with 50ng/ml rapamycin is associated with hypo-
phosphorylation of 4E-binding protein (4EBP; Figure 1D), which is a direct target of the kinase, 
mTOR (mammalian target of rapamycin).  The phosphorylation status of the cells treated with 
rapamycin was compared to the steady state (ss) condition for each cell line.  The hypo-
phosphorylation of 4EBP following rapamycin treatment of C32 and PC3, sequestrate the 
eukaryotic initiation factor 4E resulting in suppression of translation initiation efficiency.  The 
rapamycin resistant cell line A549 (Figure 1C; basal epithelial cells) was included in the study.  An 
effective dose, ED50 was reached only in PC3 at 300ng/ml rapamycin at 72hours.   
 
Perillyl alcohol is the most potent isoprenoid, suppressing cell viability at low doses 
Isoprenoids induced a loss of viability greater than 50% (effective dose, ED50) in the 3 cell lines 
tested in this study. Perillyl alcohol was the most potent isoprenoid with an effective dose ranging 
from 16 to 25 ppm at 48hours, while the effective dose of α-pinene  ranges from 32 to 54 ppm and 
that of limonene from 34 to 56 ppm at 48 hours (Figure  2).   Interestingly, the prostate cell line 
PC3 required high dose of isoprenoids at 24 hours and was as sensitive as the other cell lines at 
48 and 72 hours.   There was no significant differences in the effective doses between time point 
48 and 72 hours for the 3 cell lines, hence for the combinatory experiments measurement at 48 
hours was selected.   
Perillyl Alcohol was the  most potent  isoprenoid on all the 3 cell lines, confirming reports stating 
that Perillyl alcohol is more potent  than Limonene and is one of the most potent inhibitors of 
proliferation [31]. Cotargeting PI3K/mTOR and Ras pathways with a combination of PI3K/mTOR 
and RAS signaling pathway (MAPK)  inhibitors suggest  that  inhibition of growth  was related  to 
upregulation of proapoptotic Bim and Bad [19, 32].    
 
 
Pretreatment   with  Rapamycin  and combinatory experiments 
Rapamycin was added at a concentration of 50ng/ml to sensitise cells 24hrs prior to the addition of 
isoprenoids.  Addition of rapamycin, 24hours before treatment with isoprenoids, proved to be more 
effective than adding the drugs together (data not shown).  The combinatory treatment of 50ng/ml 
rapamycin with isoprenoids resulted in decreased ED50 of the cell lines C32 and PC3 (Table1; 
Figure 3). The combination was most effective on the PC3 cell line. 
 
Interestingly, PC3 and C32 were sensitive to rapamycin after 48hrs and not 24hrs, an observation 
that is supported in previous studies [25]. This was observed in cytotoxicity assays and in 
combinatory experiments. Rapamycin inhibits mTORC1, while mTORC2 is not affected and 
maintains  Akt/PKB  survival  signaling.  We  propose  lack  of sensitivity during the  first  24hrs to  
be Akt-driven,  forcing survival signals through  mTORC2, however, prolonged rapamycin 
treatment (48hrs and 72hrs) causes rapamycin to bind to newly synthesized free mTOR and 
interfere with mTORC2 assembly (Figure 4), downregulating Akt/PKB survival signaling [26]. 
 
 
Apoptosis  in  A549  cell line 
A549 cell line showed a marginal apoptosis induction when sensitization with 50ng/ml rapamycin, 
resulting in 11.3% apoptosis induction with  Perillyl  alcohol, compared to 5.2% when Perillyl 
Alcohol was added alone. Similar to Perillyl Alcohol, Limonene had 11.9% apoptosis induction in 
combination compared to 3.4% when added alone (Table 2).  Interestingly, although the viability 
assays indicate a significant decrease in viability following combinatory treatment in the PC3 and 
C32 cell lines, the cells do not undergo apoptosis induction as measured using Annexin V/PI 
staining.   
 
In our study, early   apoptosis   induction   was observed   when   A549   was  treated   with   
isoprenoids   in combination  with  50ng/ml  Rapamycin.  Since XTT  experiments  showed  that 
A549  was not sensitive to  rapamycin at  24hrs and 48hrs, apoptosis induction is probably neither 
due  to inhibition of mTORC1 (at 24hrs) nor mTORC2 (at 48hrs), and is largely a result of 
isoprenoid inhibition. 
 
Although cytotoxicity assays revealed sensitivity of PC3 and C32 towards rapamycin, apoptosis 
was not detected.  Antiapoptotic  proteins  like  Bcl-2 and Bcl-xL  were  reported  to  be  highly 
expressed  in PC3 cell line [27], and could be possibly induced by rapamycin treatment [28],  
supporting  the  lack  of  apoptotic  signals  observed  in annexin-V assays.  For future studies, 
protein analysis of antiapoptotic proteins Bcl-2 and Bcl-xL in rapamycin-treated cell lines, and cell 
cycle analysis measuring growth arrest at G1 by flow cytometry could have been significant in 
identifying possible loss of apoptotic signals in PC3 and C32.    A possible mechanism explaining 
our viability results is the induction of autophagy.  Inhibition of mTOR was implicated in autophagy 
induction followed by cell death [29, 30]. 
 
 
CONCLUSIONS 
 
Our results show a statistically significant reduction in ED50 of various isoprenoids, following pre-
sensitization with 50ng/ml of rapamycin in the prostate cell line (PC3) and the melanoma cell line 
(C32). Hence this novel combination of drugs targeting two mechanisms that converge on a 
common target, provide a higher efficacy compared to using either drug on its own.  This merits 
further investigation to characterise the mechanism/s of viability suppression in the solid tumour 
cellular models.  Although the mechanism of loss of viability in our study is not yet identified, we 
hypothesise that addition of rapamycin to PTEN defective cell lines, sensitise the cells for 
autophagy induction, following addition of the isoprenoids.  Of interest the rapamycin sensitized 
cell lines, have a significantly lower ED50 upon the addition of the isoprenoids used in the study 
(Table 1).  Further studies are required to understand the mechanism of cytotoxicity and a larger 
panel of cancer cell lines shall be assessed for rapamycin sensitisation.  
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FIGURE LEGENDS 
 
Figure 1. Sensitisation of PC3 and C32 using rapamycin. A, B, C: Cells were cultured in the 
presence or absence of rapamycin, using a concentration gradient from 0 to 300ng/ml.  Each data 
point is an average of three independent experiments, with triplet measurement for each 
experiment.  The standard error is indicated using error bars.  The solid lines plot the percent 
viability after 72 hours following rapamycin addition, and the dotted lines after 48 hours.  The 
melanoma [C32; A] and prostate [PC3; B] cell lines are sensitized by 50ng/ml of rapamycin.  The 
basal epithelial cell line, A549 is resistant to rapamycin, even at high concentrations.  D:  Cells 
were treated with 50ng/ml rapamycin and harvested for total cell lysates.  Western blots were 
stained with antibodies recognizing total 4EBP (4EBP Ab). The non-phosphorylated, hypo and 
hyper-phosphorylated proteins can be discriminated by their distinct electrophoretic mobility as a, 
b and g-isoforms respectively.  The steady state (ss) 4EBP phosphorylation status is also included 
for the 3 cell lines investigated [C=C32; P=PC3; A=A549].   
 
Figure 2.  Isoprenoid cytotoxic dosages.  Cells were cultured in the presence of the isoprenoids 
perillyl alcohol, limonene and α-pinene, using a concentration gradient from 0 to 160ppm.  Each 
data point is an average of three independent experiments, with triplet measurement for each 
experiment.  The open squares plot the ED50 upon addition of Limonene; the open diamonds the 
ED50 upon addition of perillyl alcohol and the solid triangles the ED50 of α-pinene.  The data show 
the time points 24, 48 and 72 hours after addition of the isoprenoid.   
 
Figure 3.   Cells were cultured in the presence of isoprenoids.  The solid lines show viability of 
cells treated with isoprenoids only, while the dotted lines plot the viability of cells upon addition of 
isoprenoids following sensitisation with 50ng/ml rapamycin.  Each data point is an average of three 
independent experiments, with triplet measurement for each experiment.  The standard error is 
indicated using error bars.  The basal epithelial cell line [A549; A, D, G]; the melanoma [C32; B, 
E, H] and prostate [PC3; C, F I] cell lines are treated with different isoprenoids, namely Perillyl 
alcohol [A, B, C]; Limonene [D,E,F]; and with α-pinene [G, H,I].  All data points are taken 
following 48 hours of isoprenoid addition.  
Figure 4.  Proposed effect of prolonged rapamycin treatment at 24hrs and 48hrs. 
Proliferation of cells continue for the first 24hrs of rapamycin treatment due to survival signals 
channeled through mTORC2/Akt pathway. Prolonged rapamycin treatment will inhibit mTORC2 
assembly and consequently Akt/PKB survival pathway, inhibiting cell proliferation.  
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Table 1 
IC50 of cell lines treated with isoprenoids alone or  in  combination with 
rapamycin.   
 
  isoprenoid  rapamycin  24h  48h  72h 
A549  Perillyl Alcohol  ‐  32  28  18 
    +  30  28  22 
  Limonene  ‐  57  55  50 
    + 54 55 52
  α‐Pinene  ‐  52  52  33 
    +  49  52  33 
PC3  Perillyl Alcohol  ‐  55  15  15 
    +  55  5  12 
  Limonene  ‐  85  45  40 
    +  67  5  5 
  α‐Pinene  ‐  67  32  30 
    +  67  5  5 
C32  Perillyl Alcohol  ‐  21  18  20 
    +  18  18  20 
  Limonene  ‐  52  33  38 
    +  22  18  23 
  α‐Pinene  ‐  21  32  32 
    +  8  15  8 
 
 
Table 2.  Apoptosis induction in A549.  
Percentages indicate AnnexinV +ve and PI -ve (early apoptosis induction) cells.  
Conditions include cells treated with Perillyl Alcohol, Limonene and  α-Pinene alone 
and  in combination with rapamycin (rapa; 50ng/ml).   
[Steady state (ss) means untreated] 
 
 
Condition  Annexin V +ve 
(%)
Steady State (ss)  1.4 
50ng/ml rapamycin  1.7 
Perillyl Alcohol  Alone  5.2 
  +rapa  11.3 
Limonene  Alone  3.4 
  +rapa  11.9 
α‐Pinene  Alone  1.9 
  +rapa  2.1
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